The safety data from Active Biotech's (Stockholm:ACTI.ST) recently concluded clinical phase II safety study shows that laquinimod, a novel oral medication for the treatment of multiple sclerosis (MS), was well tolerated also at a higher dose. The results will be presented at the 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Thessaloniki, Greece, on September 30 by the Principal Investigator, Professor Magnhild Sandberg-Wollheim.

The aim of the study was to investigate the safety of orally administered laquinimod at a higher dose (0.9 mg/day) than the dose previously shown to be effective in reducing the number of active brain lesions (0.3 mg/day) (Polman et al. Neurology 2005;64:987-991).......{CLICK FOR MORE}